FrancophonIA/ELRC3.0 huggingface dataset:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Venclyxto have been included in the summary of product characteristics and the package leaflet.
Estonian: Venclyxto ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: When Venclyxto is used on its own, treatment should continue for as long as the patient improves or remains stable and the side effects are tolerable.
Estonian: Kui Venclyxtot kasutatakse eraldi, tuleb ravi jätkata nii kaua, kuni patsiendi seisund paraneb või püsib stabiilsena ning kõrvalnähud on hallatavad.
English: The starting dose is 20 mg daily and the dose is gradually increased over 5 weeks to 400 mg.
Estonian: Algannus on 20 mg ööpäevas ja annust suurendatakse järk-järgult 5 nädala jooksul annuseni 400 mg.
English: Venclyxto (venetoclax)
Estonian: Venclyxto (venetoklaks)
English: For more information about using Venclyxto, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Venclyxto kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Venclyxto are carefully evaluated and any necessary action taken to protect patients.
Estonian: Venclyxto kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Venclyxto should be taken for 24 months from day 1 of the first cycle of rituximab.
Estonian: Venclyxtot tuleb kasutada 24 kuud alates rituksimaab-ravi esimese tsükli esimesest päevast.
English: Although there is a risk of tumour lysis syndrome, a complication that occurs when the cancer cells are being destroyed too quickly, this risk can be contained through preventive measures, such as increasing the dose gradually or reducing the dose, if needed.
Estonian: Kuigi esineb tuumori lüüsi sündroomi risk (see on tüsistus, mis tekib vähirakkude liiga kiirel lagunemisel), on see maandatav ennetusmeetmetega, näiteks annuse järkjärgulise suurendamise või annuse vähendamisega, kui vaja.
English: What is Venclyxto and what is it used for?
Estonian: Mis on Venclyxto ja milleks seda kasutatakse?
English: When Venclyxto is used in combination with rituximab, the recommended dose of Venclyxto is 400 mg once a day.
Estonian: Kui Venclyxtot kasutatakse kombinatsioonis rituksimaabiga, on Venclyxto soovitatav annus 400 mg üks kord ööpäevas.
English: Patients in this second study had all previously taken B-cell receptor pathway inhibitors.
Estonian: Selle uuringu patsiendid olid varem kasutanud B--raku retseptori raja inhibiitoreid.
English: Other information about Venclyxto
Estonian: Muu teave Venclyxto kohta
English: • patients who do not have these genetic changes after treatments with chemo-immunotherapy and a B-cell receptor pathway inhibitor have both failed.
Estonian: • Patsientidel, kellel pärast kemo-immunoteraapia ravi ei esine nimetatud geneetilisi muutusi ning kellel puudus ravivastus mõlemale B-raku retseptori raja inhibiitorile.
English: A high response rate was also seen in patients whose previous treatment with ibrutinib or idelalisib failed.
Estonian: Samuti oli ravivastusega patsientide arv suur patsientide seas, kellel ei tekkinud ravivastust varasemale ibrutiniib- või idelalisiib-ravile.
English: In another study of 127 patients with or without 17p deletion or TP53 mutation, the response rate was 70%.
Estonian: Teises uuringus, milles osales 127 patsienti, kellel esines või puudus 17p deletsioon või TP53 mutatsioon, oli ravivastusega patsiente 70%.
English: Venclyxto can be used in combination with rituximab (another cancer medicine) in patients who have received at least one previous treatment.
Estonian: Venclyxtot tohib kasutada kombinatsioonis rituksimaabiga (samuti vähiravim) patsientidel, keda on ravitud varem vähemalt üks kord.
English: In a main study of 107 previously treated patients with CLL and 17p deletion, 75% responded partially or completely to Venclyxto.
Estonian: Põhiuuringus osalenud 107 varem ravitud kroonilise lümfotsüütleukeemia ja 17p deletsiooniga patsiendist reageeris Venclyxtole täielikult või osaliselt 75%.
English: Another study in 389 patients with CLL who received at least one previous treatment showed that patients treated with Venclyxto plus rituximab lived longer without their disease getting worse (progression-free survival) than patients treated with rituximab and bendamustine (another cancer medicine).
Estonian: Veel ühes uuringus, milles osales 389 kroonilise lümfotsüütleukeemiaga patsienti, keda oli varem vähemalt kord ravitud, selgus, et patsiendid, keda raviti Venclyxto ja rituksimaabiga, elasid kauem haiguse süvenemiseta (progresseerumiseta elumus) kui patsiendid, keda raviti rituksimaabi ja bendamustiiniga (samuti vähiravim).
English: This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines.
Estonian: See valk aitab neil rakkudel organismis kauem püsida ning muudab nad vähiravimite vastu resistentseks.
English: • patients with particular genetic changes (17p deletion or TP53 mutation) that make them unsuitable for chemo-immunotherapy (a type of cancer treatment).
Estonian: • Patsientidel, kellel on teatud geneetilised muutused (17p deletsioon või TP53 mutatsioon), mille tõttu neile ei sobi kemo-immunoteraapia (vähiravi liik).
English: Studies showed patients with particular genetic mutations (17p deletion or TP53 mutations) that make them unsuitable for chemo-immunotherapy responding well to Venclyxto used on its own.
Estonian: Uuringutes tõendati, et patsiendid, kellel esinevad teatud geneetilised mutatsioonid (17p deletsioon või TP53 mutatsioonid), mis muudavad kemo-immunoteraapia neile ebasobivaks, reageerivad hästi ainuravimina kasutatavale Venclyxtole.
English: Venclyxto is a cancer medicine used to treat adults with a blood cancer known as chronic lymphocytic leukaemia (CLL).
Estonian: Venclyxto on ravim, mida kasutatakse täiskasvanutel, et ravida verevähi liiki, mida nimetatakse krooniliseks lümfotsüütleukeemiaks.
English: In these patients, Venclyxto is used when medicines known as B-cell receptor pathway inhibitors (ibrutinib and idelalisib) are not suitable or have failed.
Estonian: kui ravimid, mis on B--raku retseptori raja inhibiitorid (ibrutiniib ja idelalisiib), neile ei sobi või ei ole neil toiminud.
English: Studies have shown that a high proportion of patients have their cancer cells partially or completely cleared following treatment with Venclyxto on its own.
Estonian: Uuringutes on tõendatud, et suurel osal patsientidest on pärast ravi Venclyxtoga vähirakud täielikult või osaliselt hävinud.
English: What are the risks associated with Venclyxto?
Estonian: Mis riskid Venclyxtoga kaasnevad?
English: The most common side effects when Venclyxto is used with rituximab are low level of neutrophils, diarrhoea and nose and throat infection.
Estonian: Kõige sagedamad kõrvalnähud Venclyxto kasutamisel koos rituksimaabiga on neutropeenia, kõhulahtisus ja nina-neeluinfektsioonid.
English: For the full list of side effects with Venclyxto, see the package leaflet.
Estonian: Venclyxto kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Venclyxto contains that active substance venetoclax.
Estonian: Venclyxto sisaldab toimeainena venetoklaksi.
English: How does Venclyxto work?
Estonian: Kuidas Venclyxto toimib?
English: The most common serious side effects (seen in more than 2 in 100 people) in patients receiving Venclyxto in combination with rituximab or on its own are pneumonia (lung infection), fever associated with reduced neutrophils and tumour lysis syndrome (a complication caused by breakdown of cancer cells).
Estonian: Kõige sagedamad rasked kõrvalnähud (võivad esineda kuni 2 patsiendil 100st) patsientidel, kes kasutavad Venclyxtot kombinatsioonis rituksimaabiga või ainuravimina, on pneumoonia (kopsupõletik), neutropeeniaga seotud palavik ning tuumori lüüsi sündroom (tüsistus, mida põhjustab vähirakkude lagunemine).
English: The active substance in Venclyxto, venetoclax, attaches to a protein called Bcl-2.
Estonian: Venclyxto toimeaine venetoklaks seondub valguga Bcl-2.
English: An overview of Venclyxto and why it is authorised in the EU
Estonian: Ülevaade ravimist Venclyxto ja ELis müügiloa väljastamise põhjendus
English: Venclyxto should be started and supervised by a doctor with experience of cancer medicines and can only be obtained with a prescription.
Estonian: Venclyxto-ravi peab alustama ja jälgima vähiravis kogenud arst.
English: It can also be used on its own in:
Estonian: Samuti tohib seda kasutada ainuravimina järgmistel patsientidel.
English: The most common side effects with Venclyxto used on its own (seen in more than 1 in 5 people) are low levels of neutrophils (a type of white blood cell), diarrhoea, nausea, anaemia (low red blood cell counts), nose and throat infection and tiredness.
Estonian: Venclyxto kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on neutropeenia (neutrofiilide ehk teatud valgeliblede vähesus), kõhulahtisus, iiveldus, aneemia (erütrotsüütide ehk vere punaliblede vähesus), nina-neeluinfektsioonid ja väsimus.
English: When used in combination with rituximab, Venclyxto was shown to prolong the time patients lived without their disease getting worse.
Estonian: Uuringutes tõendati, et kombinatsioonis rituksimaabiga kasutamisel pikendas Venclyxto patsientide progresseerumiseta elumust.
English: How is Venclyxto used?
Estonian: Kuidas Venclyxtot kasutatakse?
English: Patients should have taken Venclyxto at the daily dose of 400 mg for 7 days before starting therapy with rituximab.
Estonian: Enne rituksimaabiga toimuva ravi alustamist peavad patsiendid võtma Venclyxtot 7 päeva annuses 400 mg ööpäevas.
English: What benefits of Venclyxto have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Venclyxto kasulikkus?
English: Venclyxto must not be used with medicines known as ‘strong CYP3A inhibitors' during the early stages of treatment and must also not be used with St. John's wort (a herbal preparation used to treat anxiety and depression).
Estonian: Venclyxtot ei tohi kasutada ravi varajases etapis koos ravimitega, mis on tugevatoimelised CYP3A inhibiitorid.
English: A high proportion of patients respond to Venclyxto after other treatments have failed or are unsuitable.
Estonian: Suurel osal patsientidest, kellel ei teki ravivastust muule ravile või kellele see ei sobi, tekib ravivastus Venclyxtole.
English: Safety studies have shown that the strain is safe for turkeys.
Estonian: Ohutusuuringud on tõendanud, et tüvi on kalkunitele ohutu.
English: The full EPAR for Vectormune ND can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vectormune ND kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Vectormune ND on 8 September 2015.
Estonian: Euroopa Komisjon andis Vectormune ND müügiloa, mis kehtib kogu Euroopa Liidus, 8. septembril
English: However, precautionary measures must be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Estonian: Tuleb siiski võtta ettevaatusmeetmeid, et vältida vaktsineeritud kanade otsest või kaudset kokkupuudet kalkunitega.
English: Newcastle disease and Marek's disease vaccine (live recombinant)
Estonian: Newcastle'i haiguse ja Mareki haiguse vaktsiin (elus, rekombinantne)
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vectormune ND's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Vectormune ND kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The vaccine protects against a type of Marek disease virus that can cause visible infection.
Estonian: Vaktsiin kaitseb Mareki haiguse viiruse tüübi eest, mis tekitab nähtava infektsiooni.
English: As the vaccine is stored in liquid nitrogen, it is important that any handling is done by appropriately trained personnel in a well-ventilated area and that precautions are taken when preparing the vaccine.
Estonian: Vaktsiini säilitatakse vedelas lämmastikus ja seepärast on tähtis, et seda käitleksid asjakohase väljaõppega töötajad hästi ventileeritud ruumides ja et vaktsiini ettevalmistamisel võetakse ettevaatusmeetmeid.
English: What is Vectormune ND and what is it used for?
Estonian: Mis on Vectormune ND ja milleks seda kasutatakse?
English: Vectormune ND is a veterinary vaccine used to protect chickens against Newcastle disease (ND) and Marek's disease (MD).
Estonian: Vectormune ND on veterinaarvaktsiin, mida kasutatakse kanade kaitsmiseks Newcastle'i haiguse (ND) ja Mareki haiguse (MD) eest.
English: Why is Vectormune ND approved?
Estonian: Miks Vectormune ND heaks kiideti?
English: Other information about Vectormune ND
Estonian: Muu teave Vectormune ND kohta
English: For further information see the summary of product characteristics.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes.
English: ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.
Estonian: Newcastle'i haigus (ND) on kanade viirusinfektsioon, mis põhjustab hingeldamist ja köhimist, närvisümptomeid (sorgus tiivad, pea ja kaela kõverdumine, ringliikumine ja halvatus), silmaümbruse ja kaelapiirkonna kudede turset, roheka väljaheitega vesist kõhulahtisust ning munatoodangu vähenemist.
English: In the future if the animals are exposed to a similar virus and/or to a virus expressing a similar fusion protein, the immune system will be able to respond more quickly.
Estonian: Kui kanad puutuvad hiljem viiruse ja/või sarnast fusioonvalku ekspresseerivate viirustega uuesti kokku, reageerib immuunsüsteem kiiremini.
English: It is not intended to provide practical advice on how to use Vectormune ND.
Estonian: Hindamisaruandes ei anta Vectormune ND kasutamise praktilisi nõuandeid.
English: For MD protection starts at one week of age and lasts for the risk period of infection with MD.
Estonian: Kaitse Mareki haiguse vastu algab 1 nädala vanuses ja kestab haigusesse nakatumise riskiperioodi jooksul.
English: Birds infected with MD virus can be carriers and shedders of the virus for life.
Estonian: MDviirusega nakatunud linnud võivad olla viiruse kandjad ja levitajad kogu elu.
English: The active substance in Vectormune ND is a turkey herpesvirus (rHVT/ND) that does not cause disease in chickens and has been modified so that it also produces one of the proteins of a strain of Newcastle disease virus (D-26 lentogenic strain).
Estonian: Vectormune ND toimeaine on kalkuni herpesviirus (rHVT/ND), mis ei tekita haigust kanadel ja mida on muudetud nii, et see tekitab ka Newcastle'i haiguse viiruse ühe tüve (D-26 lentogeenne tüvi) teatud valku.
English: The withdrawal period for meat and eggs from chickens treated with Vectormune ND is ‘zero' days, which means that there is no mandatory waiting time.
Estonian: Vaktsiiniga Vectormune ND ravitud kanade liha ja munade keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Vectormune ND, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Vectormune ND ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: This is a summary of the European public assessment report (EPAR) for Vectormune ND.
Estonian: See on vaktsiini Vectormune ND Euroopa avaliku hindamisaruande kokkuvõte.
English: Two field studies were conducted in around 120,000 broiler chickens to evaluate the effects of the vaccine.
Estonian: Vaktsiini toime hindamiseks tehti kaks väliuuringut ligikaudu 120 000 broileriga.
English: Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body.
Estonian: Kanad nakatuvad noorelt, hingates sisse viirust sisaldavat kõõma (nahaosakesi), mis võib olla nakkav veel mitu kuud pärast kehalt langemist.
English: For practical information about using Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Vectormune ND kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs.
Estonian: Mareki haigus (MD) on kanade herpesviiruse infektsioon, mis võib põhjustada tiibade ja jalgade halvatust ning põhjustab kasvajate teket eri elundites.
English: Since Vectormune ND is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Estonian: Vectormune ND on elusvaktsiin ja seepärast eritub vaktsiini tüvi vaktsineeritud lindudelt ja võib levida kalkunitele.
English: For ND protection starts at 3 weeks of age and lasts until 9 weeks of age for broilers (chickens bred for meat) and 18 weeks of age for layers (chickens bred for egg production).
Estonian: Kaitse Newcastle'i haiguse vastu algab 3 nädala vanuses ning kestab broileritel (lihakanadel) 9 nädala ja munakanadel 18 nädala vanuseni.
English: When Vectormune ND is given to chickens or eggs, the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Estonian: Kui kanadele või munadesse manustatakse vaktsiini Vectormune ND, peab kanade immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: What are the risks associated with Vectormune ND?
Estonian: Mis riskid vaktsiiniga Vectormune ND kaasnevad?
English: The vaccine can be given to one-day-old chicks as a single injection under the skin or directly into 18-day-old eggs containing embryos (unhatched developing chicks).
Estonian: Vaktsiini saab manustada ühepäevastele tibudele ühekordse nahaaluse süstena või otse 18 päeva vanustesse lootega munadesse.
English: Twenty-two Vectormune ND vaccinated day-old layer chickens from this study were challenged at day 21 in the laboratory with ND strain and had no clinical signs for up to 2 weeks after challenge while all of 12 unvaccinated birds used for comparison died.
Estonian: Uuringu 21. päeval nakatati laboris ND-viiruse tüvega 22 vaktsiiniga Vectormune ND vaktsineeritud ühepäevast munatibu, kellel puudusid kuni 2 nädala jooksul pärast viirusega kokkupuudet kliinilised nähud; võrdlusrühma kõik 12 vaktsineerimata lindu surid.
English: How does Vectormune ND work?
Estonian: Kuidas Vectormune ND toimib?
English: There are no known side effects with Vectormune ND.
Estonian: Vectormune ND teadaolevad kõrvalnähud puuduvad.
English: In a third field study around 10,000 one-day-old layer chickens were vaccinated with Vectormune ND and a similar number with a vaccine against ND alone.
Estonian: Kolmandas väliuuringus vaktsineeriti ligikaudu 10 000 ühepäevast munatibu vaktsiiniga Vectormune ND ja sarnane arv tibusid ainult Newcastle'i haiguse vastase vaktsiiniga.
English: The modified turkey herpesvirus in Vectormune ND is closely related to MD herpesvirus and will also produce the fusion protein which forms part of the outer coat of ND virus.
Estonian: Kalkuni herpesviiruse tüve on vaktsiinis muudetud, et see sarnaneks MDherpesviirusega ja tekitaks fusioonvalku, mis on osa ND-viiruse väliskestast.
English: What benefits of Vectormune ND have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vectormune ND kasulikkus?
English: No signs of MDV or NDV outbreaks were detected from samples taken from both groups at days 35, 66, 102 and completion at day 118.
Estonian: Mõlemast rühmast 35., 66., 102. ja 118. uuringupäeval (viimane oli uuringu lõpupäev) võtud proovides ei leitud MD- ega NDviiruse puhangute nähte.
English: Since no natural outbreaks of ND and MD occurred the chickens were challenged (exposed to infection) in the laboratory.
Estonian: Et uuringu ajal ei esinenud Newcastle'i haiguse ja Mareki haiguse puhanguid, puutusid kanad viirusega kokku laboritingimustes.
English: How is Vectormune ND used?
Estonian: Kuidas vaktsiini Vectormune ND kasutatakse?
English: Four-week-old chickens from vaccinated eggs were challenged with ND virus and 86% of the chickens were protected compared with 0-10% in the unvaccinated group.
Estonian: Vaktsineeritud munadest koorunud kanad nakatati 4-nädala vanuses ND-viirusega ning kanu, kellel esines kaitse, oli vaktsineeritud rühmas 86% ja vaktsineerimata rühmas 0-10%.
English: Four-week-old chickens from the group of one-day-old vaccinated chicks were challenged with ND virus and Vectormune ND provided protection in 95% of the chickens compared with 0-10% in the non-vaccinated group.
Estonian: Ühepäevaste tibudena vaktsineeritud rühma 4-nädalased kanad nakatati ND-viirusega ning kanu, kellel esines kaitse, oli vaktsiiniga Vectormune ND vaktsineeritud rühmas 95% ja vaktsineerimata rühmas 0-10%.
English: Nine-day-old broilers from vaccinated eggs were challenged with MD virus and 85% of the chickens were protected compared with 9% in the unvaccinated group.
Estonian: Vaktsineeritud munadest koorunud broilerid nakatati 9-päeva vanuses MD-viirusega ning kanu, kellel esines kaitse, oli vaktsineeritud rühmas 85% ja vaktsineerimata rühmas 9%.
English: In the first field study a group of 18-day-old eggs containing embryos and a group of one-day-old chicks were vaccinated with Vectormune ND.
Estonian: Esimeses väliuuringus vaktsineeriti vaktsiiniga Vectormune ND rühm 18-päevaseid viljastatud mune ja rühm ühepäevaseid tibusid.
English: In the second field study, a group of 18-day-old eggs containing embryos and a group of one-day-old chicks were vaccinated with Vectormune ND.
Estonian: Teises väliuuringus vaktsineeriti vaktsiiniga Vectormune ND rühm 18-päevaseid viljastatud mune ja rühm ühepäevaseid tibusid.
English: Nine-day-old chickens from vaccinated eggs were challenged with MD virus and 88% of the chickens were protected compared with 9-12% in the unvaccinated group.
Estonian: Vaktsineeritud munadest koorunud 9-päevased kanad nakatati MD-viirusega ning kanu, kellel esines kaitse, oli vaktsineeritud rühmas 88% ja vaktsineerimata rühmas 9-12%.
English: Nineday-old broilers from the group of chicks vaccinated at one-day-old were challenged with MD virus and 82% of the chickens were protected compared with 12% in the unvaccinated group.
Estonian: Ühepäevaste tibudena vaktsineeritud rühma 9-päevased broilerid nakatati MD-viirusega ning kanu, kellel esines kaitse, oli vaktsineeritud rühmas 82% ja vaktsineerimata rühmas 12%.
English: Nine-dayold broilers from the chicks vaccinated at one-day-old were challenged with MD virus and Vectormune ND provided protection to 90% of the chickens compared with 9-12% in the unvaccinated group.
Estonian: Ühepäevaste tibudena vaktsineeritud 9-päevased broilerid nakatati MD-viirusega ning kanu, kellel esines kaitse, oli vaktsiiniga Vectormune ND vaktsineeritud rühmas 90% ja vaktsineerimata rühmas 9-12%.
English: Vectormune ND is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Estonian: Vaktsiini Vectormune ND turustatakse süstesuspensiooni suspensiooni ja lahustina.